SCHEMBL25103299

SCHEMBL25103299

Cc1cn2cc(NC(=O)c3ccc(N4CCN(C(=O)OC(C)(C)C)CC4)c4nn(C)nc34)cc(F)c2n1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PTPN11 Q06124 1/20 0.41
▸ MAPT P10636 6/20 0.41
▸ MEN1 O00255 1/20 0.41
▸ TSHR P16473 1/20 0.41
▸ KMT2A Q03164 1/20 0.41
▸ SMN1; SMN2 Q16637 1/20 0.41
▸ BACE1 P56817 5/20 0.40
▸ THRB P10828 1/20 0.39
▸ SMPD3 Q9NY59 1/20 0.39
▸ TP53 P04637 2/20 0.38
▸ CNR1 P21554 1/20 0.38
▸ NPSR1 Q6W5P4 1/20 0.38
▸ GPR35 Q9HC97 1/20 0.38
▸ GPR55 Q9Y2T6 1/20 0.38
▸ USP30 Q70CQ3 1/20 0.38
▸ POLB P06746 1/20 0.37
▸ GALR2 O43603 1/20 0.37
▸ GALR1 P47211 1/20 0.37
▸ ALDH1A1 P00352 1/20 0.36
▸ LMNA P02545 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30312613 0.90 PTPN11 (0.44) PTPN11MAPTMEN1TSHRKMT2A
SCHEMBL25096320 0.90 PTPN11 (0.46) PTPN11MAPTMEN1TSHRKMT2A
SCHEMBL30217787 0.90 PTPN11 (0.46) PTPN11MAPTMEN1TSHRKMT2A
SCHEMBL25103265 0.89 BACE1 (0.41) PTPN11MAPTMEN1TSHRKMT2A
SCHEMBL25097071 0.89 PTPN11 (0.45) PTPN11MAPTMEN1TSHRKMT2A
SCHEMBL30217776 0.89 PTPN11 (0.45) PTPN11MAPTMEN1TSHRKMT2A
SCHEMBL31211134 0.89 PTPN11 (0.41) PTPN11MAPTMEN1TSHRKMT2A
SCHEMBL31082366 0.88 PTPN11 (0.42) PTPN11MAPTMEN1TSHRKMT2A
SCHEMBL28939445 0.88 PTPN11 (0.42) PTPN11MAPTMEN1TSHRKMT2A
SCHEMBL25096304 0.87 BACE1 (0.41) PTPN11MAPTMEN1TSHRKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250154169-A1 COMPOUNDS AND METHODS FOR MODULATING SPLICING REMIX THERAPEUTICS INC. 2025-05-15 — — US disclosed
EP-4395892-A1 COMPOUNDS AND METHODS FOR MODULATING SPLICING Remix Therapeutics Inc. (US) 2024-07-10 — — EP disclosed
CN-118302426-A Compounds and methods for modulating splicing 雷密克斯医疗公司 2024-07-05 — — CN disclosed
WO-2023034812-A1 COMPOUNDS AND METHODS FOR MODULATING SPLICING REMIX THERAPEUTICS INC. (US) 2023-03-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250154169-A1 COMPOUNDS AND METHODS FOR MODULATING SPLICING RBM17, SNRPA, SNRPA1 PTPN11 4588/4885MAPT 3414/4885MEN1 3822/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback